In silico modeling has become a ground-breaking technique in diabetes
research in recent years, offering new methods for simulating, forecasting, and
improving diabetic treatments. There is an urgent and unrelenting demand for more
individualized, effective, and timely management options given the rise in diabetes
incidence worldwide. This chapter will explore the potential of in silico modeling for
diabetes in the future, outlining all of its most recent developments, potential
innovations, and modeling pathways for collaboration with bioinformatics and
Artificial Intelligence (AI). It explores the potential implications of these developments
for the development of virtual clinical trials, insights into diabetes medication
management, and ways to overcome the barrier of validating and integrating these
models in a clinical context. We also explore the possibilities of in silico modeling for
better regimen strategy optimization and the operation of this coupled mechanisticphenomenological model with AI-bioinformatics for improved prediction and
personalization. The chapter focuses on how these cutting-edge technologies can
improve patient outcomes, clinical trial time and cost, and customized treatment. It
covers a difficult spectrum, from developing and promoting regulatory settings to
addressing the reproducibility of these models.
The future of diabetes care appears increasingly bright with the help of science-driven
advancements in bioengineering and technology-driven drivers like AI-backed
predictive analytics, multi-omics data, and virtual trial simulations.
Keywords: Artificial intelligence, Bioinformatics, Diabetes, In silico, Personalized treatment, Technological advancements.
